Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Sees Large Growth in Short Interest

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 117,659 shares, a growth of 79.6% from the June 30th total of 65,513 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 659,333 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CLPBY. The Goldman Sachs Group downgraded shares of Coloplast A/S from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold”.

Coloplast A/S Price Performance

OTCMKTS CLPBY traded down $0.08 on Friday, reaching $6.68. The company’s stock had a trading volume of 52,761 shares, compared to its average volume of 528,633. Coloplast A/S has a twelve month low of $5.64 and a twelve month high of $10.03. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.09 and a current ratio of 1.75. The firm’s 50 day moving average is $6.09 and its two-hundred day moving average is $6.85. The stock has a market cap of $15.05 billion, a PE ratio of 47.71, a PEG ratio of 2.12 and a beta of 0.22.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.01. Coloplast A/S had a net margin of 7.46% and a return on equity of 33.15%. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.11 billion. As a group, sell-side analysts predict that Coloplast A/S will post 0.38 EPS for the current year.

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.